Connecticut’s cannabis regulatory landscape has reached a boiling point as the Department of Consumer Protection (DCP) moves to suspend or revoke the grower’s license for Affinity Grow, a significant micro-cultivator based in Portland. The regulatory action, stemming from a February 24 letter, alleges that the company, operating under the name MCEJV LLC, bypassed state authorization processes by misrepresenting a specific cannabis strain known as “Cap Junky” and failed to adhere to strict solvent testing requirements. This high-stakes legal confrontation marks the latest chapter in a long-standing, contentious relationship between the state’s oversight body and one of its most vocal independent cultivators.
Key Highlights
- License in Jeopardy: The Connecticut Department of Consumer Protection (DCP) is actively pursuing the suspension or revocation of Affinity Grow’s license, citing multiple regulatory violations.
- The ‘Cap Junky’ Dispute: Regulators allege Affinity Grow attempted to bypass state authorization for a specific cannabis strain by submitting samples into the seed-to-sale tracking system without proper vetting.
- Solvent Allegations: The DCP claims the company utilized solvents in the production of at least 76 gummy products without the mandatory disclosure and subsequent testing for residual solvents.
- Company Rebuttal: Affinity Grow President Rino Ferrarese has vehemently denied the allegations, characterizing the dispute as a battle over “bad science” and regulatory overreach, asserting that the company follows the law to the letter.
- History of Tension: This legal maneuver follows a rocky history between the parties, most notably a 2025 incident involving a retaliatory, unannounced inspection of Affinity’s facility following Ferrarese’s testimony before the state legislature.
The Escalating Conflict Over Compliance and Science
The move to revoke Affinity Grow’s license is not merely a localized regulatory spat; it serves as a litmus test for the maturity of Connecticut’s legal cannabis market. As the industry transitions from the initial, experimental phase of legalization to a more rigid, enforcement-heavy period, the friction between regulators and cultivators has intensified. The DCP’s allegations against Affinity Grow center on two distinct, albeit related, issues of public safety and regulatory integrity: the manipulation of product strain tracking and the undeclared usage of chemical solvents.
The ‘Cap Junky’ Controversy
The primary grievance outlined by the DCP involves the strain “Cap Junky.” According to state regulators, Affinity Grow allegedly bypassed the mandatory state authorization process by entering five samples of this strain directly into the Cannabis Analytic Tracking System (CATS) without the requisite pre-approval. For the DCP, this is a procedural violation of the highest order. The tracking system is designed to provide a comprehensive, cradle-to-grave audit trail of all cannabis products in the state. By circumventing the authorization protocol, regulators argue that Affinity compromised the state’s ability to verify the authenticity and safety of the product before it entered the retail supply chain.
Affinity Grow, however, frames the issue differently. In statements provided to legal counsel and press, the company suggests that the DCP’s requirements are based on scientifically flawed testing methodologies. President Rino Ferrarese has consistently maintained that the company’s actions were born out of a desire to adhere to sound scientific practices, implying that the state’s testing regime—particularly regarding microbials and chemical presence—is disconnected from modern cultivation realities. By characterizing the dispute as “bad science,” Affinity is positioning itself as a defender of industry best practices against what it describes as an overly bureaucratic and technically deficient regulatory framework.
The Solvent Allegations
Beyond the strain tracking dispute, the DCP has leveled serious allegations regarding the production of 76 batches of cannabis gummies between late 2025 and December 2025. Regulators contend that Affinity Grow used solvents in the manufacturing process but failed to test these products for residual solvents, a direct violation of state statutes aimed at consumer safety. The presence of residual solvents in cannabis concentrates is a known health hazard, capable of causing respiratory issues and other adverse effects. Affinity’s defense in this matter is that they paid for full compliance testing and properly disclosed the solvent usage on the DCP’s registry, suggesting that if there is a failure, it lies within the administrative handling of the data rather than the physical manufacturing process.
The Historical Friction: A Retaliatory Context
Understanding this current threat of license revocation requires acknowledging the scorched-earth history between Affinity Grow and the DCP. In 2025, the company was the subject of an unannounced inspection that occurred merely 24 hours after Rino Ferrarese testified before the Connecticut General Law Committee in favor of legislative oversight reform. That inspection, which was later publicly condemned by DCP Commissioner Bryan Cafferelli as an action that “should not have happened,” created a narrative of institutional retaliation. This history looms large over the current proceedings. Affinity’s management argues that the present efforts to strip their license are a continuation of that retaliatory stance, designed to silence a dissenting voice within the industry.
The Economic and Regulatory Future of CT Cannabis
The implications of the Affinity Grow case extend far beyond a single business. Connecticut’s cannabis market, which has seen fluctuating sales and a legislative push for a total rewrite of the state’s cannabis code in 2026, is at a crossroads. The state is attempting to reconcile the need for high-level consumer protection with the desire to foster a viable, competitive local industry.
Stricter Enforcement or Regulatory Overreach?
Industry analysts are watching the May 12 hearing closely. If the state succeeds in revoking Affinity’s license, it will send a clear signal: the “honeymoon period” for cannabis operators in Connecticut is officially over. Regulators are moving toward a zero-tolerance policy, mirroring the stricter enforcement seen in more established markets like Colorado and California. Conversely, if Affinity successfully defends itself or negotiates a settlement, it may embolden other operators to challenge the DCP’s testing and authorization guidelines, potentially leading to a wave of litigation that could bog down the regulatory body for years.
The Impact on Consumers and the Supply Chain
While the legal battle wages, the impact on the supply chain is tangible. Products remain in limbo. The quarantine of potentially non-compliant products creates supply shortages and increases costs for the grower, who must absorb the financial loss of destroyed or unsalable inventory. For the consumer, this translates to reduced variety and, potentially, higher prices. As the state moves toward a unified code in 2026, the resolution of this case will likely serve as a foundational precedent for how the Department of Consumer Protection handles compliance disputes in the future.
FAQ: People Also Ask
Q: What is the current status of Affinity Grow’s license?
A: As of April 2026, Affinity Grow is facing a potential license suspension or revocation. A hearing, initially scheduled for March 31, has been pushed to May 12, 2026, to determine the outcome of these regulatory allegations.
Q: Why does the DCP claim the company is violating regulations?
A: The DCP alleges that Affinity Grow bypassed state tracking requirements for a strain called “Cap Junky” and failed to test 76 batches of cannabis gummies for residual solvents after using chemical processes during production.
Q: How has Affinity Grow responded to the allegations?
A: Affinity Grow, through President Rino Ferrarese, has denied any wrongdoing. The company claims it follows state laws to the letter and argues that the DCP’s testing requirements are based on flawed scientific protocols, framing the investigation as an unfair regulatory attack.
Q: What is the significance of the previous DCP inspection incident?
A: In 2025, Affinity Grow was subjected to an unannounced inspection shortly after its CEO testified to the legislature against the DCP’s proposed testing rules. The DCP Commissioner later admitted that the inspection “should not have happened,” fueling the company’s claims of institutional retaliation in the current dispute.
